J30-8

CAS No. 2366255-71-0

J30-8( —— )

Catalog No. M32969 CAS No. 2366255-71-0

J30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    J30-8
  • Note
    Research use only, not for human use.
  • Brief Description
    J30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.
  • Description
    J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    JNK
  • Recptor
    JNK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2366255-71-0
  • Formula Weight
    373.79
  • Molecular Formula
    C17H9ClFN3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 6.67 mg/mL (17.84 mM; Ultrasonic (<60°C)
  • SMILES
    Fc1ccc2NC(=O)\C(=C3/S\C(NC3=O)=N/c3ccccc3Cl)c2c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dou X, et al. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J Med Chem. 2019 Jul 25;62(14):6645-6664.?
molnova catalog
related products
  • CC-401 hydrochloride

    CC-401 hydrochloride is a potent, selective, ATP-competitive pan-JNK inhibitor with Ki of 25-50 nM.

  • GSK2879552 2HCl

    GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.

  • J30-8

    J30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.